title: Evaluating the pharmacodynamic effect of antimalarial drugs in clinical trials by quantitative PCR.
abstract: The ongoing development of new antimalarial drugs and the increasing use of controlled human malaria infection (CHMI) studies to investigate their activity in early-stage clinical trials require the development of methods to analyze their pharmacodynamic effect. This is especially so for studies where quantitative PCR (qPCR) is becoming the preferred method for assessing parasite clearance as the study endpoint. We report the development and validation of an analytic approach for qPCR-determined parasite clearance data. First, in a clinical trial with the licensed antimalarial combination sulfadoxine-pyrimethamine (S/P), qPCR data were collected from 12 subjects and used to determine qPCR replicate variability and to identify outliers. Then, an iterative analytic approach based on modeling the log-linear decay of parasitemia following drug treatment was developed to determine the parasite reduction ratio (PRR) and parasite clearance half-life, both measures of parasite clearance. This analytic approach was then validated with data from 8 subjects enrolled in a second study with the licensed antimalarial drug mefloquine. By this method, the PRR and parasite clearance half-lives for S/P and Mefloquine were determined to be 38,878 (95% confidence interval [95% CI], 17,396 to 86,889) at 3.15 (95% CI, 2.93 to 3.41) days and 157 (95% CI, 130 to 189) at 6.58 (95% CI, 6.35 to 6.83) days for the respective studies. No serious adverse events occurred in the two trials, and pharmacokinetic values were within expected ranges for sulfadoxine and pyrimethamine. The robust statistical method that we have developed to analyze qPCR-derived pharmacodynamic data from CHMI studies will facilitate the assessment of the activity of a range of experimental antimalarial drugs now entering clinical trials. (This trial was registered with the Australian New Zealand Clinical Trials Registry under registration numbers ACTRN12611001203943 and ACTRN12612000323820.).
authors.affiliation: QIMR Berghofer Medical Research Institute, Herston, QLD, Australia.
authors.forename: Louise
authors.initials: L
authors.lastname: Marquart
authors.affiliation: Medicines for Malaria Venture, Geneva, Switzerland.
authors.forename: Mark
authors.initials: M
authors.lastname: Baker
authors.affiliation: QIMR Berghofer Medical Research Institute, Herston, QLD, Australia.
authors.forename: Peter
authors.initials: P
authors.lastname: O'Rourke
authors.affiliation: QIMR Berghofer Medical Research Institute, Herston, QLD, Australia School of Medicine, University of Queensland, Herston, QLD, Australia j.mccarthy@uq.edu.au.
authors.forename: James S
authors.initials: JS
authors.lastname: McCarthy
mesh_terms: D000293:Adolescent; D000328:Adult; D000465:Algorithms; D000962:Antimalarials / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D019540:Area Under Curve; D004338:Drug Combinations; D005260:Female; D006207:Half-Life; D006801:Humans; D008288:Malaria / Q000188:drug therapy* / Q000469:parasitology*; D008297:Male; D015767:Mefloquine / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D015233:Models, Statistical; D018512:Parasitemia / Q000188:drug therapy / Q000469:parasitology; D016133:Polymerase Chain Reaction / Q000379:methods*; D011739:Pyrimethamine / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D015203:Reproducibility of Results; D013413:Sulfadoxine / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D055815:Young Adult
chemical_list: D000962:Antimalarials; D004338:Drug Combinations; C001205:fanasil, pyrimethamine drug combination; D013413:Sulfadoxine; D015767:Mefloquine; D011739:Pyrimethamine